Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Diseases ; 7(2)2019 May 25.
Artículo en Inglés | MEDLINE | ID: mdl-31130610

RESUMEN

Hereditary gingival fibromatosis is a disorder for which the etiology remains unknown. We aimed to evaluate the fibroblasts and histological alterations to give new clues. A father and a daughter of a family showing gingival hereditary fibromatosis were treated, and gingival biopsies were obtained. A histological study revealed dense fibrous tissue, basal lamina disruption, and epithelial cell migration into the connective tissue. Fibroblasts were cultured from the father and daughter and compared with those from a healthy control patient. The results of the biochemical analysis showed increased collagen synthesis, reduced antioxidant CoQ10 content, and high levels of lipid peroxidation. Additionally, fibroblasts culture incubation with the oxidant H2O2 increased collagen levels that have been reduced by the addition of the antioxidant CoQ10. We conclude that some fibroblasts metabolic alterations play a significant role in initiating and maintaining persistent fibrotic tissue. Oxidative stress influences the fibroblasts collagen production and could play a particular role in the pathogenesis of hereditary gingival fibromatosis.

2.
J Allergy Clin Immunol ; 142(4): 1131-1143.e7, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29410039

RESUMEN

BACKGROUND: Cathepsin C (CatC) is a lysosomal enzyme involved in activation of serine proteases from immune and inflammatory cells. Several loss-of-function mutations in the CatC gene have been shown to be the genetic mark of Papillon-Lefèvre syndrome (PLS), a rare autosomal recessive disease characterized by severe early-onset periodontitis, palmoplantar hyperkeratosis, and increased susceptibility to infections. Deficiencies or dysfunction in other cathepsin family proteins, such as cathepsin B or D, have been associated with autophagic and lysosomal disorders. OBJECTIVES: Here we characterized the basis for autophagic dysfunction in patients with PLS by analyzing skin fibroblasts derived from patients with several mutations in the CatC gene and reduced enzymatic activity. METHODS: Skin fibroblasts were isolated from patients with PLS assessed by using genetic analysis. Authophagic flux dysfunction was evaluated by examining accumulation of p62/SQSTM1 and a bafilomycin assay. Ultrastructural analysis further confirmed abnormal accumulation of autophagic vesicles in mutant cells. A recombinant CatC protein was produced by a baculovirus system in insect cell cultures. RESULTS: Mutant fibroblasts from patients with PLS showed alterations in oxidative/antioxidative status, reduced oxygen consumption, and a marked autophagic dysfunction associated with autophagosome accumulation. These alterations were accompanied by lysosomal permeabilization, cathepsin B release, and NLR family pyrin domain containing 3 (NLRP3) inflammasome activation. Treatment of mutant fibroblasts with recombinant CatC improved cell growth and autophagic flux and partially restored lysosomal permeabilization. CONCLUSIONS: Our data provide a novel molecular mechanism underlying PLS. Impaired autophagy caused by insufficient lysosomal function might represent a new therapeutic target for PLS.


Asunto(s)
Autofagia/efectos de los fármacos , Catepsina C/farmacología , Fibroblastos/efectos de los fármacos , Adulto , Animales , Catepsina C/genética , Células Cultivadas , Femenino , Fibroblastos/metabolismo , Humanos , Insectos , Lisosomas/metabolismo , Masculino , Mutación , Enfermedad de Papillon-Lefevre/tratamiento farmacológico , Enfermedad de Papillon-Lefevre/genética , Especies Reactivas de Oxígeno/metabolismo , Proteínas Recombinantes/farmacología , Piel/citología , Adulto Joven
3.
Int J Mol Sci ; 18(7)2017 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-28678155

RESUMEN

Periodontal disease is considered one of the main pathologic diseases occurring in humans. Its pathologic process involves inflammatory reactions producing periodontal bone resorption and the tooth loss. But some patients do not present an evident clinical inflammation with bone resorption, and in others, the inflammation is prominent without bone resorption. A key question could be to investigate a different way of responding to aggression. Inflammation requires a complex intracellular metabolic process, starting with the harmful recognition and activation of the inflammasome, continues the energy supply with the alteration of oxidative stress conditions, and finishes with the elimination of the aggression with autophagy/apoptosis mechanisms, then concludes with recovery. Peroxisome proliferator-activated receptors (PPARs) are essential molecules produced in inflammation, and its genes and its activation have been related to periodontal disease. Also, an important aspect is the influence of PPARs in bone metabolism; the main periodontitis symptom is bone loss and PPARγ activation that can downregulate the bone resorption in experimental periodontitis, PPARγ-coated titanium dental implant surfaces could carry the antiinflammatory gene and restrain inflammation. PPARs could be one of the meeting background points with atherosclerosis/cardiovascular disease, diabetes and metabolic syndrome showing a modified proinflammatory statement such as it is described in periodontitis.


Asunto(s)
Metabolismo Energético , Estado Nutricional , Enfermedades Periodontales/etiología , Enfermedades Periodontales/metabolismo , Receptores Activados del Proliferador del Peroxisoma/metabolismo , Animales , Enfermedades Óseas/etiología , Enfermedades Óseas/metabolismo , Enfermedades Óseas/patología , Susceptibilidad a Enfermedades , Humanos , Inflamasomas/metabolismo , Mitocondrias/metabolismo , Periodontitis/etiología , Periodontitis/metabolismo
4.
Antioxid Redox Signal ; 27(5): 269-275, 2017 08 10.
Artículo en Inglés | MEDLINE | ID: mdl-27967213

RESUMEN

Conventional cardiovascular risk factors (CVRFs) are accepted to identify asymptomatic individuals with high risk of acute myocardial infarction (AMI). However, AMI affects many patients previously classified at low risk. New biomarkers are needed to improve risk prediction. We propose to evaluate the NLRP3-inflammasome complex as a potential conventional cardiovascular risk (CVR) indicator in healthy males and post-AMI patients and compare both groups by known CVRFs. We included 109 men with no history of cardiovascular disease (controls) and 150 AMI patients attending a cardiac rehabilitation program. AMI patients had higher mean of body mass index (BMI) and waist circumference than the controls. However, high percentages of the controls had a high BMI and a waist circumference >95 cm. The controls also had higher systolic blood pressure (p > 0.001), total and low-density lipoprotein cholesterol, dietary nutrient, and calorific intake. Fuster BEWAT score (FBS) correlated more closely than Framingham risk score (FRS) with most CVRF, groups. However, only the FBS showed a correlation with inflammasome cytokine interleukin 1ß (IL-1ß). Several CVRFs were significantly better in AMI patients; however, this group also had higher mRNA expression of the inflammasome gene NLRP3 and lower expression of the autophagy gene MAP-LC3. The controls had high levels of CVRF, probably reflecting unhealthy lifestyle. FBS reflects the efficiency of strategies to induce lifestyle changes such as cardiac rehabilitation programs, and could provide a sensitive evaluation CVR. These results lead to the hypothesis that NLRP3-inflammasome and associated IL-1ß release have potential as CVR biomarkers, particularly in post-AMI patients with otherwise low risk scores. Antioxid. Redox Signal. 27, 269-275.


Asunto(s)
Inflamasomas/metabolismo , Infarto del Miocardio/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Adulto , Anciano , Biomarcadores , Presión Sanguínea/fisiología , Índice de Masa Corporal , Humanos , Inflamasomas/sangre , Interleucina-1beta/metabolismo , Lipoproteínas LDL/metabolismo , Masculino , Persona de Mediana Edad , Infarto del Miocardio/inmunología , Infarto del Miocardio/patología , Proteína con Dominio Pirina 3 de la Familia NLR/genética , Factores de Riesgo
5.
Exp Suppl ; 107: 129-152, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27812979

RESUMEN

The obtaining of nutrients is the most important task in our lives. Energy is central to life's evolutions; this was one of the aspect that induced the selection of the more adaptable and more energetically profitable species. Nowadays things have changed in our modern society. A high proportion of people has access to plenty amount of food and the obesity appear as one of the pathological characteristics of our society. Energy is obtained essentially in the mitochondria with the transfer of protons across the inner membrane that produce ATP. The exactly regulation of the synthesis and degradation of ATP (ATP ↔ ADP + phosphate) is essential to all form of life. This task is performed by the 5' adenosine monophosphate-activated protein kinase (AMPK). mtDNA is highly exposed to oxidative damage and could play a central role in human health and disease. This high potential rate of abnormalities is controlled by one of the most complex mechanism: the autophagy. AMPK appears to be the key cellular energy sensor involved in multiple cellular mechanisms and is essential to have a good metabolic homeostasis to face all the aggression and start the inflammatory reaction. Therefore its disturbances have been related with multiple diseases. Recent findings support the role of AMPK in inflammation and immunity such as Metabolic Syndrome, Obesity and Diabetes. All these Metabolic Disorders are considered pandemics and they need an adequate control and prevention. One important way to achieve it is deepen in the pathogenic mechanisms. Mitochondria and AMPK are the key elements through which it happen, their knowledge and research allow us to a better management. The discovery and use of drugs that can modulate them is imperative to improve our way of manage the metabolic disorders.


Asunto(s)
Proteínas Quinasas Activadas por AMP/genética , Diabetes Mellitus/genética , Síndrome Metabólico/genética , Mitocondrias/enzimología , Obesidad/genética , Proteínas Quinasas Activadas por AMP/metabolismo , Autofagia/genética , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/enzimología , Diabetes Mellitus/patología , Metabolismo Energético/genética , Regulación de la Expresión Génica , Homeostasis/genética , Humanos , Hipoglucemiantes/uso terapéutico , Inflamación , Resistencia a la Insulina/genética , Síndrome Metabólico/tratamiento farmacológico , Síndrome Metabólico/enzimología , Síndrome Metabólico/patología , Metformina/uso terapéutico , Mitocondrias/patología , Obesidad/tratamiento farmacológico , Obesidad/enzimología , Obesidad/patología , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Transducción de Señal , Tiazolidinedionas/uso terapéutico
6.
Antioxid Redox Signal ; 24(3): 157-70, 2016 Jan 20.
Artículo en Inglés | MEDLINE | ID: mdl-26132721

RESUMEN

AIMS: Impairment in adenosine monophosphate-activated protein kinase (AMPK) activity and NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation are associated with several metabolic and inflammatory diseases. In this study, we investigated the role of AMPK/NLRP3 inflammasome axis in the molecular mechanism underlying pain perception. RESULTS: Impairment in AMPK activation induced by compound C or sunitinib, two AMPK inhibitors, provoked hyperalgesia in mice (p<0.001) associated with marked NLRP3 inflammasome protein activation and increased serum levels of interleukin-1ß (IL-1ß) (24.56±0.82 pg/ml) and IL-18 (23.83±1.882 pg/ml) compared with vehicle groups (IL-1ß: 8.15±0.44; IL-18: 4.92±0.4). This effect was rescued by increasing AMPK phosphorylation via metformin treatment (p<0.001), caloric restriction diet (p<0.001), or NLRP3 inflammasome genetic inactivation using NLRP3 knockout (nlrp3(-/-)) mice (p<0.001). Deficient AMPK activation and overactivation of NLRP3 inflammasome axis were also observed in blood cells from patients with fibromyalgia (FM), a prevalent human chronic pain disease. In addition, metformin treatment (200 mg/daily), which increased AMPK activation, restored all biochemical alterations examined by us in blood cells and significantly improved clinical symptoms, such as, pain, fatigue, depression, disturbed sleep, and tender points, in patients with FM. INNOVATION AND CONCLUSIONS: These data suggest that AMPK/NLRP3 inflammasome axis participates in chronic pain and that NLRP3 inflammasome inhibition by AMPK modulation may be a novel therapeutic target to fight against chronic pain and inflammatory diseases as FM.


Asunto(s)
Proteínas Quinasas Activadas por AMP/genética , Proteínas Portadoras/genética , Fibromialgia/genética , Inflamasomas/metabolismo , Dolor/genética , Proteínas Quinasas Activadas por AMP/antagonistas & inhibidores , Proteínas Quinasas Activadas por AMP/biosíntesis , Adulto , Animales , Proteínas Portadoras/biosíntesis , Femenino , Fibromialgia/patología , Humanos , Indoles/administración & dosificación , Inflamasomas/genética , Interleucina-18/sangre , Interleucina-1beta/sangre , Masculino , Metformina/administración & dosificación , Ratones , Persona de Mediana Edad , Proteína con Dominio Pirina 3 de la Familia NLR , Dolor/patología , Percepción del Dolor/efectos de los fármacos , Fosforilación , Pirroles/administración & dosificación , Sunitinib
7.
Mitochondrion ; 21: 69-75, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25662535

RESUMEN

Fibromyalgia is a chronic pain syndrome with unknown etiology. Recent studies have shown some evidence demonstrating that oxidative stress, mitochondrial dysfunction and inflammation may have a role in the pathophysiology of fibromyalgia. Despite several skin-related symptoms accompanied by small fiber neuropathy have been studied in FM, these mitochondrial changes have not been yet studied in this tissue. Skin biopsies from patients showed a significant mitochondrial dysfunction with reduced mitochondrial chain activities and bioenergetics levels and increased levels of oxidative stress. These data were related to increased levels of inflammation and correlated with pain, the principal symptom of FM. All these parameters have shown a role in peripheral nerve damage which has been observed in FM as a possible responsible to allodynia. Our findings may support the role of oxidative stress, mitochondrial dysfunction and inflammation as interdependent events in the pathophysiology of FM with a special role in the peripheral alterations.


Asunto(s)
Fibromialgia/patología , Fibromialgia/fisiopatología , Inflamación/patología , Mitocondrias/fisiología , Estrés Oxidativo , Piel/patología , Adulto , Biopsia , Metabolismo Energético , Femenino , Humanos , Persona de Mediana Edad , Dolor/fisiopatología , Nervios Periféricos/patología
8.
Antioxid Redox Signal ; 22(8): 679-85, 2015 Mar 10.
Artículo en Inglés | MEDLINE | ID: mdl-25386668

RESUMEN

Chronic fatigue syndrome (CFS) is a chronic and extremely debilitating illness characterized by prolonged fatigue and multiple symptoms with unknown cause, diagnostic test, or universally effective treatment. Inflammation, oxidative stress, mitochondrial dysfunction, and CoQ10 deficiency have been well documented in CFS. We conducted an 8-week, randomized, double-blind placebo-controlled trial to evaluate the benefits of oral CoQ10 (200 mg/day) plus NADH (20 mg/day) supplementation on fatigue and biochemical parameters in 73 Spanish CFS patients. This study was registered in ClinicalTrials.gov (NCT02063126). A significant improvement of fatigue showing a reduction in fatigue impact scale total score (p<0.05) was reported in treated group versus placebo. In addition, a recovery of the biochemical parameters was also reported. NAD+/NADH (p<0.001), CoQ10 (p<0.05), ATP (p<0.05), and citrate synthase (p<0.05) were significantly higher, and lipoperoxides (p<0.05) were significantly lower in blood mononuclear cells of the treated group. These observations lead to the hypothesis that the oral CoQ10 plus NADH supplementation could confer potential therapeutic benefits on fatigue and biochemical parameters in CFS. Larger sample trials are warranted to confirm these findings.


Asunto(s)
Suplementos Dietéticos , Síndrome de Fatiga Crónica/tratamiento farmacológico , NAD/administración & dosificación , Ubiquinona/análogos & derivados , Administración Oral , Humanos , Ubiquinona/administración & dosificación
9.
Pharmacol Res ; 91: 1-8, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25447593

RESUMEN

Oxidative stress is implicated in several infectious diseases. In this regard, lipopolysaccharide (LPS), an endotoxic component, induces mitochondrial dysfunction and oxidative stress in several pathological events such as periodontal disease or sepsis. In our experiments, LPS-treated fibroblasts provoked increased oxidative stress, mitochondrial dysfunction, reduced oxygen consumption and mitochondrial biogenesis. After comparing coenzyme Q10 (CoQ10) and N-acetylcysteine (NAC), we observed a more significant protection of CoQ10 than of NAC, which was comparable with other lipophilic and hydrophilic antioxidants such as vitamin E or BHA respectively. CoQ10 improved mitochondrial biogenesis by activating PGC-1α and TFAM. This lipophilic antioxidant protection was observed in mice after LPS injection. These results show that mitochondria-targeted lipophilic antioxidants could be a possible specific therapeutic strategy in pharmacology in the treatment of infectious diseases and their complications.


Asunto(s)
Acetilcisteína/farmacología , Antioxidantes/farmacología , Mitocondrias/efectos de los fármacos , Ubiquinona/análogos & derivados , Adulto , Animales , Células Cultivadas , Citrato (si)-Sintasa/metabolismo , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Humanos , Peroxidación de Lípido/efectos de los fármacos , Lipopolisacáridos , Masculino , Ratones Endogámicos C57BL , Mitocondrias/metabolismo , Estrés Oxidativo/efectos de los fármacos , Consumo de Oxígeno/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Ubiquinona/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA